SCHEMBL1779655

SCHEMBL1779655

Clc1ccc(N2CCC3(CCNCC3)CC2)cc1Cl

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 3/20 0.70
CYP2D6 P10635 5/20 0.58
USP2 O75604 3/20 0.58
ALDH1A1 P00352 4/20 0.56
TSHR P16473 4/20 0.56
CYP3A4 P08684 4/20 0.56
MAPK1 P28482 2/20 0.56
HSD17B10 Q99714 2/20 0.56
TP53 P04637 2/20 0.56
CYP1A2 P05177 2/20 0.56
SMN1; SMN2 Q16637 4/20 0.50
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
ALOX12 P18054 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HTT P42858 3/20 0.46
CYP2C9 P11712 3/20 0.44
CYP2C19 P33261 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1779990 0.88 CYP2D6 (0.55) ADRB1CYP2D6USP2ALDH1A1TSHR
SCHEMBL232689 0.83 ADRB1 (1.00) ADRB1CYP2D6ALDH1A1CYP3A4TP53
SCHEMBL1779650 0.82 ADRB1 (0.53) ADRB1ALDH1A1MAPK1SMN1; SMN2MAPT
SCHEMBL1778852 0.81 CYP2D6 (0.69) ADRB1CYP2D6USP2ALDH1A1TSHR
Hydrochloric Acid SCHEMBL2959681 0.81 ADRB1 (0.96) ADRB1CYP2D6ALDH1A1CYP3A4TP53
Piperazine SCHEMBL28293494 0.81 ADRB1 (0.96) ADRB1CYP2D6ALDH1A1CYP3A4TP53
Fumaric Acid SCHEMBL1778052 0.78 USP2 (0.48) ADRB1CYP2D6USP2ALDH1A1TSHR
SCHEMBL1781288 0.76 HTR3A (0.71) CYP2D6USP2ALDH1A1TSHRCYP3A4
SCHEMBL23125230 0.75 AR (0.62) ADRB1CYP2D6USP2ALDH1A1TSHR
SCHEMBL14016410 0.75 DRD2 (0.50) ADRB1CYP2D6USP2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943630-B2 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-05-17 US claimed
EP-1917264-B1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-17 EP claimed
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors ANIONA APS (DK) 2009-04-30 US claimed
EP-1917264-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-05-07 EP claimed
WO-2007000463-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO claimed
US-7943630-B2 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-05-17 US disclosed
EP-1917264-B1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-17 EP disclosed
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors ANIONA APS (DK) 2009-04-30 US disclosed
EP-1917264-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-05-07 EP disclosed
WO-2007000463-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 ADRB1 38/4885CYP2D6 183/4885USP2 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.